...
首页> 外文期刊>Kidney international. >Hepatitis C virus-associated glomerulonephritis. Effect of [alpha]-interferon therapy
【24h】

Hepatitis C virus-associated glomerulonephritis. Effect of [alpha]-interferon therapy

机译:丙型肝炎病毒相关性肾小球肾炎。 α-干扰素治疗的效果

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Hepatitis C virus-associated glomerulonephritis. Effect of -interferon therapy. Hepatitis C virus (HCV) infection may present as a primaiy glomerular disease. We report 34 adult patients who presented with proteinuria and had circulating anti-HCV antibodies. Primary risk factors included a history of intravenous drug abuse (56%) or blood transfusion (18%). Patients presented with nephrotic syndrome (71%) or with non-nephrotic proteinuria (29%) and had membranoproliferative or acute proliferative glomerulonephritis on renal biopsy. Signs of clinical liver disease were infrequent (18%), though elevated liver function tests were common (66%) and liver biopsy in 16 of 18 patients showed chronic active hepatitis. Cryoglobulinemia was frequent (59%), but only 44% had extrarenal manifestations. In 100% of cases tested, HCV RNA could be found in the serum or cryoprecipitates. Fourteen patients received interferon alpha for 6 to 12 months with a significant reduction in proteinuria but no improvement in renal function. A good clinical response correlated with disappearance of HCV RNA from the serum during treatment; however, relapse of viremia and renal disease was common after completing therapy. Evidence for HCV infection should be sought in all patients with primary glomerular disease. The optimal treatment strategy, however, remains to be defined.
机译:丙型肝炎病毒相关性肾小球肾炎。 -干扰素治疗的效果。丙型肝炎病毒(HCV)感染可能是原发性肾小球疾病。我们报告34名成人患者出现蛋白尿和循环抗HCV抗体。主要危险因素包括静脉吸毒史(56%)或输血史(18%)。表现为肾病综合征(71%)或非肾病蛋白尿(29%)的患者,在活检时患有膜增生性或急性增生性肾小球肾炎。尽管常见的肝功能检查升高(66%),并且很少有临床肝病的迹象(18%),并且18例患者中有16例肝活检显示为慢性活动性肝炎。冻存球蛋白血症频繁(59%),但只有44%具有肾外表现。在100%的测试病例中,可以在血清或冷沉淀物中发现HCV RNA。 14名患者接受干扰素α治疗6至12个月,蛋白尿明显减少,但肾功能未见改善。良好的临床反应与治疗期间血清中HCV RNA的消失有关;然而,完成治疗后病毒血症和肾病复发很常见。所有原发性肾小球疾病患者均应寻求HCV感染的证据。然而,最佳治疗策略仍有待确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号